← FDA DRUG APPROVALS

FDA ANDA · ANDA213420

MUCUS RELIEF

guaifenesin

Sponsor: GRANULES

APPLICATION
ANDA213420
TYPE
ANDA
ORIGINAL APPROVAL
2020-05-08
LATEST ACTION
2022-12-09
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Over-the-counter

Products

GUAIFENESINOver-the-counter
GUAIFENESIN 1.2GM · TABLET, EXTENDED RELEASE · ORAL
GUAIFENESINOver-the-counter
GUAIFENESIN 600MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2022-12-09Labeling · Supplement 1 · standardAP
2020-05-08UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →